Overall Survival of Patients With Unresectable or Metastatic BRAF V600-Mutant Acral/Cutaneous Melanoma Administered Dabrafenib Plus Trametinib: Long-Term Follow-Up of a Multicenter, Single-Arm Phase IIa Trial

ObjectivesTo examine the long-term survival outcome of dabrafenib in combination with trametinib in Chinese patients with unresectable or metastatic acral/cutaneous melanoma with BRAF-V600 mutation and to explore potential predictors of effectiveness.MethodsThis was a long-term follow-up of Chinese...

全面介紹

書目詳細資料

Principais autores:	Lili Mao, Ya Ding, Xue Bai, Xinan Sheng, Jie Dai, Zhihong Chi, Chuanliang Cui, Yan Kong, Yun Fan, Yanjun Xu, Xuan Wang, Bixia Tang, Bin Lian, Xieqiao Yan, Siming Li, Li Zhou, Xiaoting Wei, Caili Li, Jun Guo, Xiaoshi Zhang, Lu Si
格式:	Artigo
語言:	Inglês
出版:	Frontiers Media S.A. 2021-08-01
叢編:	Frontiers in Oncology
主題:	melanoma dabrafenib trametinib BRAF acral melanoma
在線閱讀:	https://www.frontiersin.org/articles/10.3389/fonc.2021.720044/full
標簽:	添加標簽 沒有標簽, 成為第一個標記此記錄!